5395242025-10-012025-12-315395242025-04-012025-12-315395242025-10-012025-12-31in-capmkt:OtherExpenses1Member5395242025-10-012025-12-31in-capmkt:OtherExpenses2Member5395242025-04-012025-12-31in-capmkt:OtherExpenses1Member5395242025-04-012025-12-31in-capmkt:OtherExpenses2Member5395242025-10-012025-12-31ItemsThatWillNotBeReclassifiedToProfitAndLoss15395242025-04-012025-12-31ItemsThatWillNotBeReclassifiedToProfitAndLoss15395242025-10-012025-12-31ItemsThatWillBeReclassifiedToProfitAndLoss15395242025-04-012025-12-31ItemsThatWillBeReclassifiedToProfitAndLoss1iso4217:INRiso4217:INRxbrli:shares539524LALPATHLABNOTLISTEDINE600L01024Dr. Lal Path Labs Ltd.Main BoardEquity2025-04-012026-03-312026-01-302025-12-29INRMillionsQuarterlyThird quarterSingle segmentThe business of running laboratories for carrying out Pathological investigations of various branches of Bio-chemistry, Hematology, Histopathology, Microbiology, Electrophoresis, Immuno-chemistry, Immunology, Virology, Cytology, other pathological and radiological investigations.2026-01-3011:10:002026-01-3013:10:00Not applicable2025-10-012025-12-31UnauditedConsolidated65980000002440000006842000000128700000000134500000072000000421000000217300000052980000001544000000-3010000001243000000395000000-66000000329000000091400000000009140000003000000917000000905000000900000090800000090000001676000000105.425.41005.425.41i. The above consolidated results were reviewed by the Audit Committee and approved by the Board of Directors in their respective meetings held on 30 January, 2026. The limited review, as required under Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, has been completed by the Statutory Auditors for the quarter and nine months ended December 31, 2025 and they have expressed an unmodified conclusion on the aforesaid results. <BR> <BR> ii. The above consolidated results represent consolidated results of the Company and its subsidiaries (together referred to as 'the Group'). <BR> <BR> <BR> iii. These financial results of the Group have been prepared in accordance with the recognition and measurement principles laid down in the Accounting Standard 34 "Interim Financial Reporting" ("Ind AS 34"), prescribed under Section 133 of the Companies Act, 2013 read with relevant rules issued thereunder and other accounting principles generally accepted in India. <BR> <BR> iv. During the nine months ended 31 December 2025, the Parent Company has issued 183,775 equity shares of face value of INR 10 each , to "Dr. Lal Pathlabs Employee Welfare Trust" under Employee Stock Option Plan, 2022 ("ESOP Plan, 2022"). <BR> <BR> <BR> v. The Board of Directors of the Parent Company have approved third interim dividend of INR 3.5 per equity share (face value of INR 10 each) at their meeting held on 30 January, 2026. <BR> <BR> The Board of Directors of the Parent Company had approved second interim dividend of INR 7 per equity share (face value of INR 10 each) at their meeting held on 31 October, 2025 which was paid on 17 November,2025. <BR> <BR> The Board of Directors of the Parent Company had approved an interim dividend of INR 6 per equity share (face value of INR 10 each) at their meeting held on 31 July, 2025 which was paid on 14 August, 2025 <BR> <BR> The Board of Directors of the Parent Company had proposed final dividend of INR 6 per equity share (face value of INR 10 each) for the financial year ended 31 March, 2025. The same was approved by the shareholders in the Annual General Meeting held on 28 June, 2025 and this was paid on 2 July, 2025. <BR> vi. During the year ended 31 March 2025, Dr. Lal PathLabs Kenya Private Limited (Wholly Owned Subsidiary), a Company incorporated in the Republic of Kenya, was dissolved and its name was struck off, with effect from the date of publication of gazette notification dated 13 September, 2024. <BR> <BR> vii. The Hon’ble Allahabad Bench of the National Company Law Tribunal (‘Hon’ble Tribunal’ or ‘NCLT’) sanctioned the Scheme of Amalgamation ('Scheme') between the subsidiaries Paliwal Medicare Private Limited (PMPL) (Transferor Company) and Paliwal Diagnostics Private Limited (PDPL) (Transferee Company) on 3 September, 2024. The appointed date as per Scheme was 1 April, 2021. The Scheme had envisaged transfer of all properties, rights, assets, interests and claims of the Transferor Company to the Transferee Company.Pursuant to the Scheme becoming effective, the amalgamation had been accounted for under the ‘pooling of interests’ method in accordance with Ind AS 103 “Business Combinations” and the assets, liabilities and reserves of the Transferor Company had been accounted for at their book value, in the books of Transferee Company. <BR> <BR> viii. The Board of the Parent Company had earlier noted approval by the board of Suburban Diagnostics India Private Limited ("SDIPL"), a wholly owned subsidiary of the Company for voluntary liquidation of SDIPL under the provisions of Insolvency and Bankruptcy Code, 2016, wherein the business undertaking of SDIPL was sought to be distributed to the Company on a going concern basis. The shareholders of SDIPL at their Extra-Ordinary General Meeting held on 6 February, 2025 also accorded approval for the voluntary liquidation of SDIPL. On 18 March, 2025, the liquidator of SDIPL based on the approved scheme has distributed the entire business undertaking of SDIPL to the Company, on a going concern basis. <BR> <BR> The above distribution resulted in inter-alia recognition of long term service agreements in block of intangible assets in tax books of the Company at fair value on 18 March, 2025. Accordingly, deferred tax credit of INR 408 million has been recognised in statement of profit or loss for the quarter and year ended 31 March 2025. <BR> <BR> ix. The shareholders of the Parent Company on December 07, 2025 had approved, through postal ballot, the issuance of bonus shares, in the proportion of 1:1, i.e. 1 (One) bonus equity share of Rs.10 each for every 1 (One) fully paid-up equity share held as on the record date. The Board of Director's had fixed December 19, 2025 as record rate. Accordingly, the entity has allotted 8,37,75,510 bonus equity shares on December 22, 2025 by capitalizing share premium. In accordance with the 'Ind AS 33 - Earnings per Share', the figures of Earnings Per Share for the quarter September 30, 2025 and year ended March 31, 2025 and quarter/nine months ended December 31, 2024 have been restated to give effect to the allotment of the bonus shares. <BR> x. On November 21, 2025, the Government of India notified provisions of the Code on Wages, 2019, the Industrial Relations Code, 2020, the Code on Social Security, 2020 and the Occupational Safety, Health and Working Conditions Code, 2020, (‘Labour Codes’) which consolidate twenty-nine existing labour laws into a unified framework governing employee benefit during employment and post-employment. The Labour Codes, amongst other things, introduces changes, including a uniform definition of wages and enhanced benefits relating to leave. The Group has assessed and estimated the financial implications of these changes which has resulted in increase in gratuity liability arising out of past service cost and increase in leave liability by 301 Million. Considering the impact arising out of an enactment of the new legislation is an event of non-recurring nature, the Group has presented this incremental amount as “Impact of Labour Codes” under “Exceptional Item” in the Consolidated Statement of Profit and Loss for the three months and nine months ended December 31, 2025. The Group continues to monitor the developments pertaining to Labour Codes and will evaluate impact if any on the measurement of liability pertaining to employee benefits. <BR> <BR> xi. As at 31st December,2025, the Parent company has the following subsidiaries: <BR> <BR> Subsidiaries <BR> Paliwal Diagnostics Private Limited <BR> Dr. Lal PathLabs Nepal Private Limited <BR> Dr. Lal Path Labs Bangladesh Private Limited <BR> Dr. Lal Ventures Private Limited <BR> PathLabs Unifiers Private Limited <BR> <BR> Step-down subsidiaries <BR> Centrapath Labs Private Limited <BR> APRL PathLabs Private Limited <BR> Chanre Laboratory Private Limited <BR> <BR> JV/Associate Company- Nil <BR> <BR> xii. The Board of Directors, which has been identified as being the chief operating decision maker (CODM), evaluates the Group's performance, allocates resources based on the analysis of the various performance indicators of the Group as a single unit. Therefore there is no reportable segment for the Group, in accordance with the requirements of Indian Accounting Standard 108 - 'Operating Segments', notified under the Companies (Indian Accounting Standard) Rules, 2015. <BR> 2025-04-012025-12-31UnauditedConsolidated2060200000077300000021375000000399400000000399000000016700000011720000006661000000159840000005391000000-30100000050900000001318000000-4000000131400000003776000000000037760000009000000378500000037350000004100000037440000004100000016760000001022.3822.350022.3822.35Fees to collection centers/channel partners958000000Other expenses1215000000Fees to collection centers/channel partners2943000000Other expenses3718000000Remeasurement of the defined benefit obligations40000004000000Remeasurement of the defined benefit obligations100000001000000010000003000000Exchange differences on translation of foreign operations00Exchange differences on translation of foreign operations200000020000000030000009000000